| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Angela Peron, Kit Sing Au, Hope Northru. Genetics, genomics, and genotype-phenotype correlations of TSC: Insights for clinical practice. American journal of medical genetics. Part C, Seminars in medical genetics. vol 178. issue 3. 2019-09-27. PMID:30255984. |
tuberous sclerosis complex (tsc) is a multisystem autosomal dominant condition caused by inactivating pathogenic variants in either the tsc1 or the tsc2 gene, leading to hyperactivation of the mtor pathway. |
2019-09-27 |
2023-08-13 |
Not clear |
| David Neal Franz, Darcy Andrew Kruege. mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex. American journal of medical genetics. Part C, Seminars in medical genetics. vol 178. issue 3. 2019-09-27. PMID:30307123. |
mtor inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex. |
2019-09-27 |
2023-08-13 |
drosophila_melanogaster |
| David Neal Franz, Darcy Andrew Kruege. mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex. American journal of medical genetics. Part C, Seminars in medical genetics. vol 178. issue 3. 2019-09-27. PMID:30307123. |
these developments are summarized and the practical use of mtor inhibitors to improve the lives of patients with tuberous sclerosis reviewed. |
2019-09-27 |
2023-08-13 |
drosophila_melanogaster |
| Piero Perucca, Emilio Perucc. Identifying mutations in epilepsy genes: Impact on treatment selection. Epilepsy research. vol 152. 2019-08-27. PMID:30870728. |
everolimus, an mtor inhibitor approved for the treatment of focal seizures associated with tuberous sclerosis complex, is an example of a medication targeting the etiological mechanisms of the disease. |
2019-08-27 |
2023-08-13 |
Not clear |
| Robert Waltereit, Martha Feucht, Magdalena C de Vries, Julia Huemer, Veit Roessner, Petrus J de Vrie. [Neuropsychiatric manifestations in Tuberous Sclerosis Complex (TSC): diagnostic guidelines, TAND concept and therapy with mTOR inhibitors]. Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie. vol 47. issue 2. 2019-08-22. PMID:30080117. |
[neuropsychiatric manifestations in tuberous sclerosis complex (tsc): diagnostic guidelines, tand concept and therapy with mtor inhibitors]. |
2019-08-22 |
2023-08-13 |
Not clear |
| Robert Waltereit, Martha Feucht, Magdalena C de Vries, Julia Huemer, Veit Roessner, Petrus J de Vrie. [Neuropsychiatric manifestations in Tuberous Sclerosis Complex (TSC): diagnostic guidelines, TAND concept and therapy with mTOR inhibitors]. Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie. vol 47. issue 2. 2019-08-22. PMID:30080117. |
neuropsychiatric manifestations in tuberous sclerosis complex (tsc): diagnostic guidelines, tand concept and therapy with mtor inhibitors abstract. |
2019-08-22 |
2023-08-13 |
Not clear |
| Tohru Okanishi, Ayataka Fujimoto, Mitsuyo Nishimura, Shinpei Baba, Shinji Itamura, Kazuo Okanari, Hideo Enok. [The Efficacy of Everolimus for Refractory Seizures in Childhood Onset Epilepsy with Tuberous Sclerosis Complex]. Brain and nerve = Shinkei kenkyu no shinpo. vol 71. issue 6. 2019-08-07. PMID:31171758. |
everolimus is a mammalian target of rapamycin (mtor) inhibitor that has cytoreductive effects on subependymal giant cell astrocytoma and renal angiomyolipoma in tuberous sclerosis complex (tsc). |
2019-08-07 |
2023-08-13 |
Not clear |
| Chu-Jen Kuo, Chi-Chen Huang, Szu-Yi Chou, Yu-Chun Lo, Tzu-Jen Kao, Nai-Kuei Huang, Connie Lin, Hsin-Chuan Lin, Hui-Ching Lin, Yi-Chao Le. Potential therapeutic effect of curcumin, a natural mTOR inhibitor, in tuberous sclerosis complex. Phytomedicine : international journal of phytotherapy and phytopharmacology. vol 54. 2019-06-11. PMID:30668362. |
potential therapeutic effect of curcumin, a natural mtor inhibitor, in tuberous sclerosis complex. |
2019-06-11 |
2023-08-13 |
Not clear |
| Chu-Jen Kuo, Chi-Chen Huang, Szu-Yi Chou, Yu-Chun Lo, Tzu-Jen Kao, Nai-Kuei Huang, Connie Lin, Hsin-Chuan Lin, Hui-Ching Lin, Yi-Chao Le. Potential therapeutic effect of curcumin, a natural mTOR inhibitor, in tuberous sclerosis complex. Phytomedicine : international journal of phytotherapy and phytopharmacology. vol 54. 2019-06-11. PMID:30668362. |
recent studies suggest that curcumin inhibit mtor activity in vitro, which prompts us to investigate curcumin function as a new class of mtor inhibitor suitable for tuberous sclerosis complex (tsc) treatment. |
2019-06-11 |
2023-08-13 |
Not clear |
| Hiroko Kotajima-Murakami, Toshiyuki Kobayashi, Hirofumi Kashii, Atsushi Sato, Yoko Hagino, Miho Tanaka, Yasumasa Nishito, Yukio Takamatsu, Shigeo Uchino, Kazutaka Iked. Effects of rapamycin on social interaction deficits and gene expression in mice exposed to valproic acid in utero. Molecular brain. vol 12. issue 1. 2019-06-10. PMID:30621732. |
the overactivation of mtor has been implicated in the pathogenesis of syndromic autism spectrum disorder (asd), such as tuberous sclerosis complex (tsc). |
2019-06-10 |
2023-08-13 |
mouse |
| Jun Zhan, Raghu K Chitta, Frank C Harwood, Gerard C Grosvel. Phosphorylation of TSC2 by PKC-δ reveals a novel signaling pathway that couples protein synthesis to mTORC1 activity. Molecular and cellular biochemistry. vol 456. issue 1-2. 2019-05-17. PMID:30684133. |
downstream of insulin-like growth factor receptor, the tsc1/2/ tcb1d7 (tuberous sclerosis complex) and mtor (mechanistic target of rapamycin) pathways are implicated in many human diseases, including cancer and diabetes. |
2019-05-17 |
2023-08-13 |
human |
| Kara L Calkins, Shanthie Thamotharan, Yun Dai, Bo-Chul Shin, Satish C Kalhan, Sherin U Devaska. Early dietary restriction in rats alters skeletal muscle tuberous sclerosis complex, ribosomal s6 and mitogen-activated protein kinase. Nutrition research (New York, N.Y.). vol 54. 2019-05-03. PMID:29685622. |
in ipdr and pndr, a reduction in tuberous sclerosis complex 2 may explain why mtor was unchanged, whereas, in males, an increase in mapk with a decrease in rs6 may suggest a block in mapk signaling. |
2019-05-03 |
2023-08-13 |
rat |
| Samer Alsidawi, Pashtoon Murtaza Kas. Exceptional response to everolimus in a novel tuberous sclerosis complex-2 mutation-associated metastatic renal-cell carcinoma. Cold Spring Harbor molecular case studies. vol 4. issue 2. 2019-05-01. PMID:29610387. |
patients with tuberous sclerosis complex (tsc) syndrome can also develop rcc primarily mediated through mtor signaling. |
2019-05-01 |
2023-08-13 |
Not clear |
| Anat Bachar Zipori, Nasrin N Tehrani, Asim Al. Retinal astrocytoma regression in tuberous sclerosis patients treated with everolimus. Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus. vol 22. issue 1. 2019-04-23. PMID:29277498. |
everolimus is an inhibitor of the mammalian target of rapamycin (mtor) that has been approved by the us food and drug administration for the treatment of subependymal giant cell astrocytoma (sega) in patients with tuberous sclerosis complex (tsc). |
2019-04-23 |
2023-08-13 |
Not clear |
| Min Li, Ying Zhou, Chaoyang Chen, Ting Yang, Shuang Zhou, Shuqing Chen, Ye Wu, Yimin Cu. Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis. Orphanet journal of rare diseases. vol 14. issue 1. 2019-04-19. PMID:30760308. |
efficacy and safety of mtor inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis. |
2019-04-19 |
2023-08-13 |
Not clear |
| Min Li, Ying Zhou, Chaoyang Chen, Ting Yang, Shuang Zhou, Shuqing Chen, Ye Wu, Yimin Cu. Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis. Orphanet journal of rare diseases. vol 14. issue 1. 2019-04-19. PMID:30760308. |
the treatment of tuberous sclerosis complex (tsc) using mammalian target of rapamycin (mtor) inhibitors is clinically promising. |
2019-04-19 |
2023-08-13 |
Not clear |
| Yong Wang, Juan Liu, Jie-Sen Zhou, Hua-Qiong Huang, Zhou-Yang Li, Xu-Chen Xu, Tian-Wen Lai, Yue Hu, Hong-Bin Zhou, Hai-Pin Chen, Song-Min Ying, Wen Li, Hua-Hao Shen, Zhi-Hua Che. MTOR Suppresses Cigarette Smoke-Induced Epithelial Cell Death and Airway Inflammation in Chronic Obstructive Pulmonary Disease. Journal of immunology (Baltimore, Md. : 1950). vol 200. issue 8. 2019-04-10. PMID:29507104. |
expression of mtor was significantly decreased and its suppressive signaling protein, tuberous sclerosis 2 (tsc2), was increased in the airway epithelium of human copd and in mouse lungs with chronic cs exposure. |
2019-04-10 |
2023-08-13 |
mouse |
| Zhouyang Li, Yinfang Wu, Hai-Pin Chen, Chen Zhu, Lingling Dong, Yong Wang, Huiwen Liu, Xuchen Xu, Jiesen Zhou, Yanping Wu, Wen Li, Songmin Ying, Huahao Shen, Zhi-Hua Che. MTOR Suppresses Environmental Particle-Induced Inflammatory Response in Macrophages. Journal of immunology (Baltimore, Md. : 1950). vol 200. issue 8. 2019-04-05. PMID:29563176. |
mechanistically, pm activated mtor through modulation of erk, akt serine/threonine kinase 1, and tuberous sclerosis complex signals, whereas mtor deficiency further enhanced the pm-induced necroptosis and activation of subsequent nf κ light-chain-enhancer of activated b cells (nfkb) signaling. |
2019-04-05 |
2023-08-13 |
mouse |
| Bozena Kuzniewska, Krzysztof Sadowski, Katarzyna Urbanska, Malgorzata Urbanska, Katarzyna Kotulska, Ewa Liszewska, Wieslawa Grajkowska, Sergiusz Jóźwiak, Magdalena Dziembowsk. The level of microRNA 21 is upregulated by rapamycin in serum of tuberous sclerosis complex patients and subependymal giant cell astrocytoma (SEGA)-derived cell cultures. Folia neuropathologica. vol 56. issue 3. 2019-03-28. PMID:30509037. |
tuberous sclerosis complex (tsc) represents a genetic condition, in which the clinical manifestations are caused by the disinhibition of the mammalian target of rapamycin (mtor) pathway due to mutations in the tsc1 (hamartin) or tsc2 (tuberin) genes. |
2019-03-28 |
2023-08-13 |
Not clear |
| James P Madigan, Feng Hou, Linlei Ye, Jicheng Hu, Aiping Dong, Wolfram Tempel, Marielle E Yohe, Paul A Randazzo, Lisa M Miller Jenkins, Michael M Gottesman, Yufeng Ton. The tuberous sclerosis complex subunit TBC1D7 is stabilized by Akt phosphorylation-mediated 14-3-3 binding. The Journal of biological chemistry. vol 293. issue 42. 2019-03-20. PMID:30143532. |
the tuberous sclerosis complex (tsc) is a negative regulator of mtor complex 1, a signaling node promoting cellular growth in response to various nutrients and growth factors. |
2019-03-20 |
2023-08-13 |
Not clear |